Keytruda

New trial data for Keytruda in triple-negative breast cancer

Keytruda plus chemotherapy showed significant and meaningful improvement. Merck &Co – known as MSD outside the US and Canada – has revealed additional data for its blockbuster immunotherapy for high-risk, early-stage ... The new results – from the

NICE recommends Keytruda for colorectal cancer patients with rare mutations

In addition, 48.3% of patients receiving Keytruda lived 24 or months without their cancer progressing, compared with 18.6% in the chemotherapy group. ... We are pleased, therefore, to be able to recommend [Keytruda] for routine use in the NHS,” he added

FDA approval for Keytruda/Herceptin combination in first-line advanced gastric cancer

The US Food and Drug Administration (FDA) has approved Merck &Co’s Keytruda plus Roche’s Herceptin and chemotherapy in the first-line setting for HER2-positive advanced gastric or gastroesophageal ... From the start of Keytruda’s development, we

Merck & Co reveals plans for women’s health spinoff Organon

namely blockbuster checkpoint inhibitor Keytruda (pembrolizumab) – but will also “enable necessary investments”.

Pfizer’s COVID-19 vaccine yields $3.5bn in first quarter sales

plus Merck &Co’s checkpoint inhibitor Keytruda for the first-line treatment of advanced renal cell carcinoma (RCC).

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]